p-value (MIN-101 vs placebo) Effect size (MIN-101 vs placebo) Endpoint at 12 weeks 32mg 64mg 32mg 64mg Primary objective 5-Factor Negative Score (i.e., Negative Symptoms, Pentagonal Structure): 0.0240 0.0036 0.45 0.57 Secondary objectives PANSS total score 0.0819 0.0031 0.34 0.57 3-Factor Negative Score 0.0064 0.0004 0.54 0.70 3-Factor Positive Score 0.4018 0.3067 0.16 0.20 3-Factor General Psychopathology Score 0.2359 0.0034 0.23 0.56 5-Factor Positive Score 0.5045 0.2146 -0.13 0.24 5-Factor Dysphoric Mood Score 0.5644 0.0266 0.11 0.43 5-Factor Activation Score 0.0240 0.0118 0.44 0.49 5-Factor Autistic Preoccupation Score 0.6700 0.2408 0.08 0.22 CGI-S* (severity) 0.0982 0.0234 0.35 0.43 CGI-I** (improvement) 0.2378 0.0032 0.33 0.57 BNSS (Brief Negative Symptom Scale) 0.0869 0.0040 0.33 0.56 Brief Assessment of Cognition in Schizophrenia (Total Score) 0.0388 0.5947 0.40 0.10 BACS cognition assessment (Composite T Score) 0.2737 0.8253 0.21 -0.04 - Token Motor Test 0.0306 0.0493 0.42 0.38 - Motor Function: Symbol Coding Task 0.6310 0.0781 0.09 0.33 - Verbal Fluency: Semantic Fluency 0.0299 0.1838 0.42 0.25 - Verbal Fluency: Letter Fluency 0.0328 0.0878 0.41 0.32 - Total Verbal Fluency 0.0076 0.0554 0.51 0.36 - Verbal Memory 0.1544 0.3158 0.27 0.19 Executive Function: Tower of London 0.3988 0.1952 0.16 0.25 Exploratory objectives CDSS depression scale 0.1756 0.0091 0.25 0.46 PSP personal and social performance - Socially Useful Activities 0.4775 0.0601 0.14 0.38 - Personal & Social Relationships 0.9174 0.0129 0.02 0.53 - Self-care 0.1736 0.0210 0.27 0.46 - Disturbing & Aggressive Behavior 0.0532 0.0057 0.36 0.51 Bold red text indicates p-value < 0.05 * Analyzed using ranked data: change from Baseline and ES are based on observed change from baseline data ** Analyzed using ranked data; ES is based on observed data Final results of MIN-101 Phase IIb efficacy analyses Exhibit 99.2